The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care.

It is the medical school for the Mount Sinai Health System, which includes seven hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Our unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels us ever forward in biomedical discoveries and advances. We pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. We make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

Since it opened in 1968, the School, led by Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai and President for Academic Affairs, Mount Sinai Health System, has become a world-class leader in medical education, research, and patient care.

• The School is made up of 36 multidisciplinary research, educational, and clinical Institutes and 33 academic Departments
• Annual budget: $2.7 billion
• Named 4th among “World’s Most Innovative Companies in Data Science” by Fast Company magazine in 2016
• More than 6,369 full-time, part-time, and voluntary faculty
• 5,640 people employed full-time by the School (excluding faculty)

Who We Are

At ISMMS we train the physicians and scientists of tomorrow while we conduct breakthrough research and provide multidisciplinary clinical care.

Academic Community

• 561 medical students
• 93 MD/PhD students
• 222 PhD students
• 349 master's degree students
• 575 Postdoctoral Fellows

Another Day, Another Breakthrough

Our investigators conduct groundbreaking research with funding support that moves discoveries from the bench to the bedside and from the lab to the marketplace.

• $318.4 million in National Institutes of Health (NIH) funding awarded to our researchers in 2017
  • Ranked 13th among U.S. medical schools for NIH funding
  • Ranked 2nd in research dollars per principal investigator among U.S. medical schools by the Association of American Medical Colleges (AAMC)
• Mount Sinai Innovation Partners helps bring many discoveries to market
• 17 marketed products and technologies including FluMist vaccine, Fabrazyme®, a treatment for Fabry disease, and the Annuloplasty Ring, a device for repairing heart valves
• 12 products currently in the development